Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer

[1]  G. Ferbeyre,et al.  SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma , 2016, Prostate Cancer and Prostatic Diseases.

[2]  G. Ferbeyre,et al.  Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21CIP1/WAF1 in the liver , 2016, Oncogene.

[3]  K. Rudolph,et al.  p21 shapes cancer evolution , 2016, Nature Cell Biology.

[4]  N. Maitland,et al.  The molecular and cellular origin of human prostate cancer. , 2016, Biochimica et biophysica acta.

[5]  C. Miranti,et al.  The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. , 2016, Cellular signalling.

[6]  R. Montironi,et al.  AR-V7 and prostate cancer: The watershed for treatment selection? , 2016, Cancer treatment reviews.

[7]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[8]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[9]  H. G. van der Poel,et al.  Androgen receptor profiling predicts prostate cancer outcome , 2015, EMBO molecular medicine.

[10]  Jae-Hoon Jeong,et al.  Suppressor of Cytokine Signaling (SOCS) Genes Are Silenced by DNA Hypermethylation and Histone Deacetylation and Regulate Response to Radiotherapy in Cervical Cancer Cells , 2015, PloS one.

[11]  M. Yeganeh,et al.  Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma , 2015, Oncogene.

[12]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[13]  J. Korbel,et al.  Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer , 2014, International journal of cancer.

[14]  A. Sharma,et al.  The Role of Suppressors of Cytokine Signalling in Human Neoplasms , 2014, Molecular biology international.

[15]  Lei Shi,et al.  Hepatocellular carcinoma‐associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4‐miR155‐SOCS1‐MMP9 axis , 2013, Hepatology.

[16]  A. Ward,et al.  SOCS proteins in development and disease. , 2013, American journal of clinical and experimental immunology.

[17]  A. Goldstein,et al.  Adaptation or selection—mechanisms of castration-resistant prostate cancer , 2013, Nature Reviews Urology.

[18]  H. Hirano,et al.  Identification of miR-30d as a novel prognostic maker of prostate cancer , 2012, Oncotarget.

[19]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[20]  G. Ferbeyre,et al.  SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. , 2011, Journal of hepatology.

[21]  C. Logothetis,et al.  The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials , 2011, Expert opinion on investigational drugs.

[22]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[23]  Edward T Kipreos,et al.  CRL2(LRR-1) targets a CDK inhibitor for cell cycle control in C. elegans and actin-based motility regulation in human cells. , 2010, Developmental cell.

[24]  Dan Sun,et al.  STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. , 2010, World journal of gastroenterology.

[25]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[26]  W. Jiang,et al.  Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer , 2010, BMC Cancer.

[27]  Shuai Jiang,et al.  MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.

[28]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[29]  Frédérick A. Mallette,et al.  SOCS1 links cytokine signaling to p53 and senescence. , 2009, Molecular cell.

[30]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[31]  L. Kenner,et al.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. , 2009, The American journal of pathology.

[32]  Kenta Nakai,et al.  PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.

[33]  B. Berghuis,et al.  A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[34]  Brett Kahr.  Tissues , 2008, On Practising Therapy at 1.45 A.M..

[35]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[36]  Ganesh Venkatraman,et al.  Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. , 2008, Cancer letters.

[37]  E. Schiffer.  Biomarkers for prostate cancer , 2007, World Journal of Urology.

[38]  Yuzhuo Wang,et al.  The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. , 2007, Cancer research.

[39]  A. Gazdar,et al.  Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. , 2006, Cancer letters.

[40]  L. Flowers,et al.  A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells , 2005, Oncogene.

[41]  C. Martínez-A,et al.  CXCR4-mediated Suppressor of Cytokine Signaling Up-regulation Inactivates Growth Hormone Function* , 2004, Journal of Biological Chemistry.

[42]  S. Reed,et al.  Prostein expression is highly restricted to normal and malignant prostate tissues , 2004, The Prostate.

[43]  P. Humphrey,et al.  Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.

[44]  Jan-Gowth Chang,et al.  Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia , 2003, British journal of haematology.

[45]  R. Hruban,et al.  Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms , 2003, British Journal of Cancer.

[46]  Soo Young Park,et al.  15d-PGJ2 and Rosiglitazone Suppress Janus Kinase-STAT Inflammatory Signaling through Induction of Suppressor of Cytokine Signaling 1 (SOCS1) and SOCS3 in Glia* , 2003, The Journal of Biological Chemistry.

[47]  R. Rottapel,et al.  Regulation of cytokine receptor signaling by SOCS1 , 2003, Immunological reviews.

[48]  Douglas S Scherr,et al.  High expression of the Met receptor in prostate cancer metastasis to bone. , 2002, Urology.

[49]  S. Balk,et al.  Androgen receptor as a target in androgen-independent prostate cancer. , 2002, Urology.

[50]  E. Vazquez,et al.  p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. , 2002, Carcinogenesis.

[51]  Warren S. Alexander,et al.  Suppressors of cytokine signalling (SOCS) in the immune system , 2002, Nature Reviews Immunology.

[52]  T. McDonnell,et al.  The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[54]  J. Herman,et al.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.

[55]  P. Humphrey,et al.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. , 1995, The American journal of pathology.

[56]  P. Troncoso,et al.  c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.

[57]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[58]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .